Overview

Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment

Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
This study is designed to test the efficacy of tailored operative or non-operative management (NOM) for MRI defined low-risk rectal cancer following neoadjuvant intensity modulated radiotherapy with concurrent capecitabine plus consolidation CapeOX. The main purpose of this study is to increase organ-preservation rate for low-risk rectal cancer patients.
Details
Lead Sponsor:
Beijing Cancer Hospital
Treatments:
Capecitabine
Oxaliplatin